Fulgent Genetics Valuation
| FLGT Stock | USD 17.78 0.35 1.93% |
At this time, the firm appears to be undervalued. Fulgent Genetics shows a prevailing Real Value of $19.17 per share. The current price of the firm is $17.78. Our model computes the value of Fulgent Genetics from reviewing the firm fundamentals such as Profit Margin of (0.14) %, current valuation of 237.45 M, and Shares Outstanding of 30.44 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Fulgent Genetics' valuation include:
Price Book 0.488 | Enterprise Value | Enterprise Value Ebitda (4.34) | Price Sales 1.8873 | Forward PE 7.9365 |
Undervalued
Today
Please note that Fulgent Genetics' price fluctuation is not too volatile at this time. Calculation of the real value of Fulgent Genetics is based on 3 months time horizon. Increasing Fulgent Genetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Fulgent Genetics' intrinsic value may or may not be the same as its current market price of 17.78, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 17.78 | Real 19.17 | Target 22.67 | Hype 17.78 | Naive 17.26 |
The intrinsic value of Fulgent Genetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Fulgent Genetics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Fulgent Genetics helps investors to forecast how Fulgent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fulgent Genetics more accurately as focusing exclusively on Fulgent Genetics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Fulgent Genetics' intrinsic value based on its ongoing forecasts of Fulgent Genetics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Fulgent Genetics' closest peers.
Fulgent Genetics Cash |
|
Fulgent Valuation Trend
Fulgent Genetics' real value is important for investors to make better decisions and a more accurate overall view of Fulgent Genetics' financial worth over time. Using both Fulgent Genetics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Fulgent Valuation Data Drivers
Fulgent Genetics Total Value Analysis
Fulgent Genetics is currently forecasted to have valuation of 237.45 M with market capitalization of 541.29 M, debt of 8.47 M, and cash on hands of 515.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Fulgent Genetics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
237.45 M | 541.29 M | 8.47 M | 515.4 M |
Fulgent Genetics Investor Information
About 33.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulgent Genetics has Price/Earnings To Growth (PEG) ratio of 1.32. The entity recorded a loss per share of 1.33. The firm had not issued any dividends in recent years. Based on the key indicators related to Fulgent Genetics' liquidity, profitability, solvency, and operating efficiency, Fulgent Genetics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Fulgent Genetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fulgent Genetics has an asset utilization ratio of 23.24 percent. This implies that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Fulgent Genetics is more efficient with each dollar of assets it utilizes for everyday operations.Fulgent Genetics Ownership Allocation
Fulgent Genetics holds a total of 30.44 Million outstanding shares. Over half of Fulgent Genetics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fulgent Genetics Profitability Analysis
The company reported the previous year's revenue of 283.47 M. Net Loss for the year was (43.82 M) with profit before overhead, payroll, taxes, and interest of 113.46 M.About Fulgent Genetics Valuation
The stock valuation mechanism determines Fulgent Genetics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Fulgent Genetics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fulgent Genetics. We calculate exposure to Fulgent Genetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fulgent Genetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 107.2 M | 174.3 M | |
| Pretax Profit Margin | (0.18) | (0.17) | |
| Operating Profit Margin | (0.26) | (0.25) | |
| Net Loss | (0.15) | (0.16) | |
| Gross Profit Margin | 0.38 | 0.42 |
Fulgent Genetics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Fulgent Genetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 30.2 M | |
| Quarterly Earnings Growth Y O Y | -0.986 | |
| Forward Price Earnings | 7.9365 |
Fulgent Genetics Current Valuation Indicators
Fulgent Genetics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Fulgent Genetics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Fulgent Genetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Fulgent Genetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Fulgent Genetics' worth.Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.